AbolerIS Pharma announces publication in Journal of Clinical Investigation on preclinical and translational data supporting use in Autoimmune PolyEndocrinopathy Candidiasis Ectodermal Dystrophy syndrome (APECED or APS-1).
Our Approach
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.
Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.
IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.
Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.
Our Company
Our Vision
Founders
- 37 years experience in basic and translational immunology
- Co-head of Inserm Team 2 at the INSERM-CRTI Research Center
- Director of Research at INSERM
- Senior advisor to AbolerIS
- 18 years experience in basic and translational immunology
- Co-head of Inserm Team 2 at the INSERM-CRTI Research Center
- Director of Research at CNRS
- Senior advisor to AbolerIS
Dr. F.-Xavier HUBERT (MD, PhD)
- 15 years experience in basic and translational immunology.
- 22 publications in tolerance and autoimmunity, h index of 19
- Medical Degree, University of Nantes (internship in Angers University) 2017
- PhD in Immunology, Nantes, 2005
- Member of AbolerIS’ Board
Management
Board of Directors
Founder and CEO of Teneobio (Palo Alto US), serial entrepreneur and mAb developer
Professor of Immunology and Pharmacotherapy at ULB (Belgium), head of the Institute for Interdisciplinary Innovation in Healthcare (I3h)
F.Xavier Hubert, MD, PhD
15 years experience in basic and translational immunology
